{
    "clinical_study": {
        "@rank": "3146", 
        "arm_group": [
            {
                "arm_group_label": "Quetiapine", 
                "arm_group_type": "Experimental", 
                "description": "Quetiapine 100 mg (Seroquel, Tablet)"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Experimental", 
                "description": "Moxifloxacin 400 mg (Avelox, Tablet)"
            }, 
            {
                "arm_group_label": "Escitalopram", 
                "arm_group_type": "Experimental", 
                "description": "Escitalopram 20 mg (Lexapro, Tablet)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Water intake"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the corrected QT interval change(automatic-reading) after single oral\n      administration of escitalopram, quetiapine and moxifloxacin versus placebo in healthy Korean\n      Adults."
        }, 
        "brief_title": "Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Randomized, Open-label, Placebo-controlled, 4-way crossover study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy subjects aged 20 - 40 years.\n\n          2. A body weight in the range of 50 kg (inclusive) - 90 kg (inclusive) and a body mass\n             index (BMI) in the range 19.0 kg/m2 (inclusive) - 25.0 kg/m2 (inclusive).\n\n          3. Sufficient ability to understand the nature of the study and any hazards of\n             participating in it. Provide written informed consent after being fully. informed\n             about the study procedures.\n\n        Exclusion Criteria:\n\n          1. Presence or history of hypersensitivity or allergic reactions to drugs including\n             investigational product (Escitalopram, Quetiapine, Moxifloxacin)) or other quinolone\n             group antibiotics.\n\n          2. Subject judged not eligible for study participation by investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871701", 
            "org_study_id": "CNSQT"
        }, 
        "intervention": [
            {
                "arm_group_label": "Escitalopram", 
                "description": "Escitalopram", 
                "intervention_name": "Escitalopram", 
                "intervention_type": "Drug", 
                "other_name": "Escitalopram 20 mg (Lexapro, Tablet)"
            }, 
            {
                "arm_group_label": "Quetiapine", 
                "description": "Quetiapine", 
                "intervention_name": "Quetiapine", 
                "intervention_type": "Drug", 
                "other_name": "Quetiapine 100 mg (Seroquel, Tablet)"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "Moxifloxacin", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Moxifloxacin 400 mg (Avelox, Tablet)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "Water intake"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram", 
                "Quetiapine", 
                "Psychotropic Drugs", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Corrected QT interval prolongation", 
            "Psychotropic drugs"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seongnam", 
                    "country": "Korea, Republic of", 
                    "state": "Gyounggi"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin", 
        "overall_official": {
            "affiliation": "Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Korea", 
            "last_name": "Jae-Yong Chung, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry for Health, Welfare and Family Affairs", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Corrected QT interval prolongation", 
            "safety_issue": "Yes", 
            "time_frame": "Predose (3 times) and 1, 2, 3, 4, 6, 8, 12, 16, 24 h, additional 26, 28, 32, 48 h after escitalopram dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871701"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Bundang Hospital", 
            "investigator_full_name": "Jae Yong Chung", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC, Cmax, Tmax, t1/2, CL/F", 
                "measure": "AUC (area under the plasma concentration-time curve) of escitalopram", 
                "safety_issue": "No", 
                "time_frame": "Predose and 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48h postdose"
            }, 
            {
                "description": "AUC, Cmax, Tmax, t1/2, CL/F", 
                "measure": "AUC (area under the plasma concentration-time curve)of quetiapine, moxifloxacin", 
                "safety_issue": "No", 
                "time_frame": "Predose and 1, 2, 3, 4, 6, 8, 12, 16, 24 h postdose"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Seoul National University Bundang Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}